Bel­gium firm ex­pands clin­i­cal plat­form to APAC

BioSpectrum (Asia) - - Company News -

Bel­gium-based cancer di­ag­nos­tics firm Vo­li­tion has ex­panded the clin­i­cal trial pro­gramme of its Nu.Q plat­form, be­ing de­vel­oped to de­tect col­orec­tal cancer, to the Asia Pa­cific Re­gion. The ex­pan­sion in­cludes the ex­e­cu­tion of agree­ments with the Na­tional Tai­wan Univer­sity (NTU) to carry out two multi-coun­try, multi-cen­tre stud­ies in multi-eth­nic Asian par­tic­i­pants. Nu.Q is de­signed as a se­ries of sim­ple, cost-ef­fec­tive and ac­cu­rate blood tests which an­a­lyse sam­ples for the pres­ence of early nu­cle­o­some markers of cancer. This is in­tended to fa­cil­i­tate early di­ag­no­sis and treat­ment. The two tri­als be­ing per­formed at the univer­sity, will in­volve 5,000 asymp­to­matic and 2,000 symp­to­matic col­orec­tal cancer pa­tients, re­spec­tively. Their main ob­jec­tive is to val­i­date the ca­pa­bil­ity of Nu.Q to de­tect and di­ag­nose col­orec­tal cancer, for mar­ket­ing pur­poses. Re­cently, Vo­li­tion also ex­e­cuted an agree­ment with the Na­tional Univer­sity of Sin­ga­pore to con­duct a 719-sub­ject trial.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.